Events | October 14, 2021
FICCI annual healthcare conference from Oct. 20-22nd 2021
This is a virtual event and the theme is `Transforming Healthcare beyond Covid’
This is a virtual event and the theme is `Transforming Healthcare beyond Covid’
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
The initiative, with the support of MoHFW, will directly impact a population of more than 5.7 million that depend on the public health value chain across the 10 districts
As of FY21, it is the largest independent medical device company and the second-largest company overall, in the surgical consumables market in India with a 7.91 per cent share based on the value
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Turnover of API division of ISLL stood at Rs 856.58 crore
Subscribe To Our Newsletter & Stay Updated
